Behavioral Rehabilitation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
|出版商||Mordor Intelligence Pvt Ltd||商品編碼||1008399|
|出版日期||內容資訊||英文 116 Pages
|行為康復市場-增長、趨勢、COVID-19 影響和預測（2021-2026） Behavioral Rehabilitation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)|
|出版日期: 2021年05月13日||內容資訊: 英文 116 Pages||
在 2021 年至 2026 年的預測期內，行為康復市場預計將以 3.5% 的複合年增長率穩定增長。
COVID-19 大流行預計將對市場產生輕微的負面影響。目前，世界各國都面臨著 COVID-19 的嚴重威脅。許多製藥和生物技術公司將研發工作重點放在消毒劑和疫苗的製造上，以滿足客戶不斷增長的需求。由於這種情況，大多數製藥和生物技術公司都將其研發部門集中在識別治療這種疾病的新分子或先導物上。
許多國家/地區已經批准了 COVID-19 疫苗。例如，2020 年 12 月，世界衛生組織 (WHO) 宣佈在全球範圍內驗證輝瑞/BioNTech 的 COVID-19 mRNA 疫苗以供緊急使用。根據 Katya Numbers 等人於 2021 年 1 月發表在 Nature Reviews Neurology 上的一項研究，癡呆症等精神障礙患者存在認知症狀，難以遵守保護程序和生活環境。 COVID-19 感染的風險。在長期護理機構中，它促進了病毒的傳播。此外，患有癡呆症的老年人比沒有癡呆症的老年人更容易出現嚴重的疾病後果。根據路易體協會的說法，患有癡呆症和相關疾病的人應該洗手、保持推薦的物理距離、監測 COVID-19 的症狀、待在家裡等，以防止病毒傳播。它指出很難遵循政府制定的指導方針。由於短期記憶喪失和認知障礙，患有更嚴重癡呆症的人可能無法理解或記住指南。根據 2020 年國家統計局的數據，據報導，癡呆症和阿爾茨海默病是英國與 COVID-19 相關的最常見的既往死亡。
The Behavioral Rehabilitation Market is estimated to grow with a steady CAGR of 3.5 % during the forecast period from 2021-2026.
The COVID-19 pandemic is expected to have a slightly negative impact on the market. At present, countries across the globe are facing a considerable threat of COVID-19 (coronavirus). Many pharmaceutical and biotechnological companies are focusing their R&D activities on manufacturing antiseptic products and vaccines to meet the increased demand from customers. Owing to the situation, most pharmaceutical and biotechnological companies have been focusing their R&D departments on identifying new molecules or leads for the treatment of this disease. Many countries have already approved a vaccine for COVID-19. For instance, in December 2020, the World Health Organization (WHO) issued the emergency use validation of Pfizer/BioNTech COVID-19 mRNA vaccine globally. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology in January 2021, stated that people with mental disorders like dementia are at high risk of COVID-19 infection because cognitive symptoms cause difficulty with following safeguarding procedures and living arrangements in care homes facilitate viral spread. Furthermore, older population with dementia are also more likely to have more severe disease consequences than those without dementia. As per Lewy Body Society, stated that people with dementia and related disorders find harder to follow government guidelines designed to prevent the spread of the virus such as washing hands, maintaining the recommended physical distance, monitoring COVID-19 symptoms and staying at home. People with more severe dementia may not be able to understand or remember the guidelines due to their short-term memory loss and cognitive impairment. As per Office for National Statistics UK 2020, stated that dementia and Alzheimer's disease were the most common pre-existing conditions found among deaths involving COVID-19 in United Kingdom.
Furthermore, due to the COVID-19 pandemic, lots of families are facing a significant economic burden, which can lead to an even greater inclination toward letting go of treatment options. Moreover, the pandemic can also have a negative impact on the new product launches, which are estimated to be the most prominent factor of the growth of the market. For instance, in April 2020, Biogen announced that it had delayed Alzheimer's and dementia drug filing to FDA while citing the complexity of data analysis and impact on COVID-19 on its R&D resources
According to the statistics provided by the Mental Health Foundation in 2018, mental health problems were one of the primary causes of rising medical concerns. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the age group of 20-29 years, since the past few decades. According to the same source, every year, a large number of people were diagnosed with mental illnesses in the United States. According to the United States Department of Health and Human Services (DHHS) in 2018, one in every five (20%) children and adolescents suffer from mental health disorder at some point in their life. At least, 1 in 10, or about 6 million people suffered serious emotional disturbance at some point in their life.
The treatments for behavioural disorders mainly focuses on behavioural treatment and medication. Parent management training and family therapy are considered quite effective for managing behavioural disorders. Additionally, cognitive behavioral therapy treatment is the most commonly used mechanism for managing the symptoms of behavioral disorders. However, medication treatment for these disorders is targeted toward treating underlying or co-occurring disorders, such as attention deficit hyperactivity disorder (ADHD), depression or anxiety. These developments re expected to positively affect market development.
Anxiety Disorder is Expected to Significant Share of the Global Behavioral Rehabilitation Market Over the Forecast Period
The anxiety disorders are different from normal feelings of anxiousness and involve excessive anxiety or fear. According to Our World in Data (OWID), an estimated 284 million people experienced an anxiety disorder in 2017, globally, making it the most prevalent mental health or neurodevelopmental disorder. Whereas, the Anxiety and Depression Association of America (ADAA) states that anxiety disorders are the most common mental illness in the United States, affecting 40 million adults of age 18 and older, i.e., 18.1% of the population each year. Even though anxiety disorders are very much treatable, only 36.9% of those suffering receive treatment, according to the Anxiety and Depression Association of America. Individuals with an anxiety disorder are three to five times more likely to visit the doctor and six times more likely to be hospitalized for psychiatric conditions than those who do not have anxiety disorders. The roots of anxiety disorders are presently unknown but probably involve a combination of factors, including genetic, psychological, environmental, and developmental.
However, many antidepressants, including escitalopram (Lexapro) and fluoxetine (Prozac), can alleviate anxiety disorders and help people lead a normal and productive life. Furthermore, increase in research and development on treatment of anxiety disorders due to overall increasing prevalence of this disorder is expected to drive the market growth over the forecast period.
North America is Expected to Hold the Major Share of the Market Over the Forecast Period
North America is the largest behavioral rehabilitation market in the world, with the United States occupying the major share. The developed countries, including the United States and Canada, have been witnessing a large number of mental health rehabilitation centers opening for the past decade. According to the NIH, in the United States, the prevalence of personality disorder was 9.1%. As per the National Institute of Mental Health, 2018, in the United States, 21.4% of American adults have experienced mood disorders at some point in their lives. It has also been found that there are various new launches in the behavioral health market in North America. For instance, in September 2019, Hackensack Meridian Health launched the first medically integrated urgent care center with behavioral health in the country, with an aim to improve access, better coordinate care, and innovate treatment for people struggling with mental health issues and addiction. Therefore, in addition, favorable government initiatives and a large number of reimbursement options are two of the other factors fueling growth in this region. The Affordable Care Act categorizes behavioral disorders as essential healthcare, which helps in covering the major part of the treatments. Therefore, all these factors affect the growth of the market.
The market is slightly consolidated with a few major players. Currently, many companies are focusing on the development and introduction of novel products and services into the market which is easily affordable and accessible and entering into strategic collaborations and partnerships to enhance their market positions. Some of the key innovations in the market are: In February 2019, Acadia Healthcare acquired the operations and real estate associated with Whittier Pavilion, a premier behavioral healthcare facility located in Haverhill, Massachusetts, and Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona, and Oklahoma.